Stock ANIK ANIKA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Anika Therapeutics, Inc.

Equities

ANIK

US0352551081

Real-time Estimate Cboe BZX
Other stock markets
 03:42:22 2024-06-10 pm EDT 		5-day change 1st Jan Change
25.72 USD -0.29% Intraday chart for Anika Therapeutics, Inc. -3.67% +13.42%
May. 30 Caligan Partners Enters into a Cooperation Agreement with Anika Therapeutics CI
May. 28 Anika Therapeutics Approves $40 Million Share Repurchase Program MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Barrington Ups Price Target on Anika Therapeutics to $37 From $29, Keeps Outperform Rating
MT
Barrington Ups Price Target on Anika Therapeutics to $29 From $28, Reiterates Outperform Rating
MT
Barrington Ups PT on Anika Therapeutics to $28 From $24, Expecting JPR Business to Produce 'Double-digit, Top-line Growth', Maintains Outperform Rating
MT
Barrington Upgrades Anika Therapeutics to Outperform From Market Perform, Saying 'Downdraft in Shares Seems Materially Overdone,' Price Target is $24
MT
Stephens Adjusts Price Target on Anika Therapeutics to $23 From $28, Maintains Equal-Weight Rating
MT
Barrington Research Downgrades Anika Therapeutics to Market Perform From Outperform After Full-Year 2023 Forecast Below Expectations
MT
Barrington Research Downgrades Anika Therapeutics to Market Perform From Outperform
MT
Barrington Upgrades Anika Therapeutics to Outperform From Market Perform, Price Target is $31
MT
Stephens Reinstates Anika Therapeutics at Equalweight With $26 Price Target
MT
Stephens Downgrades Anika Therapeutics to Equalweight from Overweight, Adjusts Price Target to $35 from $50
MT
Stephens Starts Anika Therapeutics at Overweight With $55 Price Target
MT
Barrington Adjusts Price Target on Anika Therapeutics to $48 From $44, Keeps Outperform Rating
MT
ANIKA THERAPEUTICS : UBS Starts Anika Therapeutics at Neutral With $46 Price Target
MT
ANIKA THERAPEUTICS : Barrington Research Upgrades Anika Therapeutics to Outperform From Market Perform; Price Target is $43
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANIK Stock
  4. News Anika Therapeutics, Inc.
  5. Analyst Reco.